A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell.

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Frans M. Verduyn Lunel,

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

How to Treat MDS without Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Tania.

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival Ashok Srinivasan, William Mitchell,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan.

Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High- Risk Allogeneic Transplant Recipients Sheila Serafino, Navneet S. Majhail,

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Impact of Extremely Long Driving Distance on Distress and Physical Function in Hematopoietic Cell Transplant Recipients Rahul Banerjee, Jean C. Yi, Navneet.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

B Cells and Transplantation: An Educational Resource

Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe Shahram.

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Biology of Blood and Marrow Transplantation

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Ensi Voshtina,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Infection Prevention - Visitors and the Best of Intentions

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index Joumana Kmeid, Jakapat.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA) Samer.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity.

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Development of an Assessment Tool for Patient Evaluation Prior to Hematopoietic Stem Cell Transplantation (HSCT) Jaskiran Kaur, Madhu Ragupathi, Eric.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest Maheen Z. Abidi, Cassandra Stoll, Anita D'Souza,

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid.

Presentation transcript:

A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients: The REACT Study Ella J. Ariza-Heredia, Dimpy P. Shah, Drew J. Winston, Scott D. Rowley, Kathleen M. Mullane, Pranatharthi Chandrasekar, Robin K. Avery, Parameswaran Hari, Karl S. Peggs, Deepali Kumar, Rajneesh Nath, Per T. Ljungman, Sherif B. Mossad, Sanjeet S. Dadwal, William Cruikshank, Firas El Chaer, Roy F. Chemaly Biology of Blood and Marrow Transplantation Volume 23, Issue 3, Pages S46-S47 (March 2017) DOI: 10.1016/j.bbmt.2016.12.011 Copyright © 2016 Terms and Conditions

Figure 1 % of patients with first reactivation. Biology of Blood and Marrow Transplantation 2017 23, S46-S47DOI: (10.1016/j.bbmt.2016.12.011) Copyright © 2016 Terms and Conditions

Figure 2 Median T-SPOT response. Biology of Blood and Marrow Transplantation 2017 23, S46-S47DOI: (10.1016/j.bbmt.2016.12.011) Copyright © 2016 Terms and Conditions

Figure 3 First Reaction vs Median T-SPOT Reconstitution. Biology of Blood and Marrow Transplantation 2017 23, S46-S47DOI: (10.1016/j.bbmt.2016.12.011) Copyright © 2016 Terms and Conditions